NeuroPace (NPCE) Stock Price, News & Analysis

Company Overview

NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.

Key Stats

• Today's Range: $8.65 to $9.17
• 50-Day Range: $8.25 to $11.14
• 52-Week Range: $5.45 to $18.98
• Volume: 156,232 shs
• Average Volume: 216,525 shs
• Market Capitalization: $297.39 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $16.60
• Consensus Rating: Moderate Buy

NeuroPace Stock Analysis - MarketRank™

NeuroPace scored higher than 70% of companies evaluated by MarketBeat, and ranked 301st out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

NeuroPace has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

NeuroPace has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for NeuroPace are expected to grow in the coming year, from ($1.00) to ($0.90) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of NeuroPace is -10.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of NeuroPace is -10.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

NeuroPace has a P/B Ratio of 15.24. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.89% of the float of NeuroPace has been sold short.

Short Interest Ratio / Days to Cover

NeuroPace has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in NeuroPace has recently increased by 23.81%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

NeuroPace does not currently pay a dividend.

Dividend Growth

NeuroPace does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

4.89% of the float of NeuroPace has been sold short.

Short Interest Ratio / Days to Cover

NeuroPace has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in NeuroPace has recently increased by 23.81%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.8 / 5
• News Sentiment: 0.84

News Sentiment

NeuroPace has a news sentiment score of 0.84. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.66 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 14 news articles for NeuroPace this week, compared to 4 articles on an average week.

Search Interest

1 people have searched for NPCE on MarketBeat in the last 30 days.

MarketBeat Follows

2 people have added NeuroPace to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, NeuroPace insiders have not sold or bought any company stock.

Percentage Held by Insiders

20.50% of the stock of NeuroPace is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

78.83% of the stock of NeuroPace is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

NPCE Stock Analysis - Frequently Asked Questions

How have NPCE shares performed this year?

NeuroPace's stock was trading at $11.19 on January 1st, 2025. Since then, NPCE stock has decreased by 19.7% and is now trading at $8.99.

How were NeuroPace's earnings last quarter?

NeuroPace, Inc. (NASDAQ:NPCE) posted its earnings results on Tuesday, August, 12th. The company reported ($0.26) earnings per share for the quarter, missing analysts' consensus estimates of ($0.24) by $0.02. The firm had revenue of $23.52 million for the quarter, compared to analyst estimates of $23.08 million. NeuroPace had a negative trailing twelve-month return on equity of 168.61% and a negative net margin of 29.29%.
Read the conference call transcript.

When did NeuroPace IPO?

NeuroPace (NPCE) raised $85 million in an initial public offering (IPO) on Thursday, April 22nd 2021. The company issued 5,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Morgan Stanley served as the underwriters for the IPO and Wells Fargo and SVB Leerink were co-managers.

Who are NeuroPace's major shareholders?

NeuroPace's top institutional shareholders include Orbimed Advisors LLC (7.97%), Soleus Capital Management L.P. (6.99%), First Light Asset Management LLC (4.21%) and Armistice Capital LLC (3.51%). Insiders that own company stock include Accelmed Partners Ii LP, Orbimed Advisors Llc, Martha Morrell and Ltd Kck.
View institutional ownership trends.

How do I buy shares of NeuroPace?

Shares of NPCE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of NeuroPace own?

Based on aggregate information from My MarketBeat watchlists, some other companies that NeuroPace investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE), e.l.f. Beauty (ELF) and Jabil (JBL).

Company Calendar

• Last Earnings: 8/12/2025
• Today: 8/23/2025
• Next Earnings (Estimated): 11/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:NPCE
• CIK: 1528287
• Web: www.neuropace.com
• Phone: 650-237-2700
• Fax: N/A
• Employees: 170
• Year Founded: N/A

Price Target and Rating

• Average Price Target for NeuroPace: $16.60
• High Price Target: $18.00
• Low Price Target: $15.00
• Potential Upside/Downside: +84.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.83
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.84)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$27.14 million
• Net Margins: -29.29%
• Pretax Margin: -29.29%
• Return on Equity: -168.61%
• Return on Assets: -25.48%

Debt

• Debt-to-Equity Ratio: 3.02
• Current Ratio: 5.47
• Quick Ratio: 4.51

Sales & Book Value

• Annual Sales: $79.91 million
• Price / Sales: 3.72
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.59 per share
• Price / Book: 15.24

Miscellaneous

• Outstanding Shares: 33,080,000
• Free Float: 26,299,000
• Market Cap: $297.39 million
• Optionable: Optionable
• Beta: 1.89